Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
17
OCS Quote, Financials, Valuation and Earnings
Last price:
$27.69
Seasonality move
:
-4.37%
Day range:
$26.91 - $28.70
52-week range:
$14.00 - $30.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.76x
Volume:
367.4K
Avg. volume:
330.2K
1-year change:
54.09%
Market cap:
$1.6B
Revenue:
--
EPS (TTM):
-$2.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
$158K | -$0.53 | -- | -33.13% | $48.15 |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.30 | 27.83% | 6689.47% | $409.68 |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
$27.72 | $48.15 | $1.6B | -- | $0.00 | 0% | -- |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 19.33x | $0.00 | 0% | 3.46x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1700 | -- | $8.4M | 5.90x | $0.00 | 0% | 0.61x |
|
ONC
BeOne Medicines Ltd.
|
$299.02 | $409.68 | $33.1B | 118.52x | $0.00 | 0% | 6.33x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$21.15 | -- | $274.4M | 1.45x | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
1.17% | 0.965 | 0.25% | 5.80x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.818 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.557 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.078 | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
31.44% | 0.327 | 5.95% | 2.98x |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -7.351 | -- | 0.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OCS
Oculis Holding AG
|
-- | -$26.3M | -68.19% | -68.98% | -- | -$18M |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.3B | $185.8M | 5.51% | 7.54% | 12.35% | $381.2M |
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
Oculis Holding AG vs. Competitors
-
Which has Higher Returns OCS or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to Oculis Holding AG's net margin of --. Oculis Holding AG's return on equity of -68.98% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.53 $250.4M BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About OCS or BPMUF?
Oculis Holding AG has a consensus price target of $48.15, signalling upside risk potential of 69.28%. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Oculis Holding AG has higher upside potential than Basilea Pharmaceutica AG, analysts believe Oculis Holding AG is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is OCS or BPMUF More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.327, suggesting its less volatile than the S&P 500 by 67.337%.
-
Which is a Better Dividend Stock OCS or BPMUF?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or BPMUF?
Oculis Holding AG quarterly revenues are --, which are larger than Basilea Pharmaceutica AG quarterly revenues of --. Oculis Holding AG's net income of -$29.4M is higher than Basilea Pharmaceutica AG's net income of --. Notably, Oculis Holding AG's price-to-earnings ratio is -- while Basilea Pharmaceutica AG's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 3.46x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$29.4M BPMUFBasilea Pharmaceutica AG3.46x 19.33x -- --
-
Which has Higher Returns OCS or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to Oculis Holding AG's net margin of --. Oculis Holding AG's return on equity of -68.98% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.53 $250.4M CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About OCS or CSBTF?
Oculis Holding AG has a consensus price target of $48.15, signalling upside risk potential of 69.28%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Oculis Holding AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Oculis Holding AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is OCS or CSBTF More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.447%.
-
Which is a Better Dividend Stock OCS or CSBTF?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or CSBTF?
Oculis Holding AG quarterly revenues are --, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. Oculis Holding AG's net income of -$29.4M is higher than Kuros Biosciences Ltd.'s net income of --. Notably, Oculis Holding AG's price-to-earnings ratio is -- while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$29.4M CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns OCS or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Oculis Holding AG's net margin of --. Oculis Holding AG's return on equity of -68.98% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.53 $250.4M ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About OCS or ELVAF?
Oculis Holding AG has a consensus price target of $48.15, signalling upside risk potential of 69.28%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Oculis Holding AG has higher upside potential than EvoNext Holdings SA, analysts believe Oculis Holding AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is OCS or ELVAF More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -40.297, suggesting its less volatile than the S&P 500 by 4129.699%.
-
Which is a Better Dividend Stock OCS or ELVAF?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or ELVAF?
Oculis Holding AG quarterly revenues are --, which are larger than EvoNext Holdings SA quarterly revenues of --. Oculis Holding AG's net income of -$29.4M is higher than EvoNext Holdings SA's net income of --. Notably, Oculis Holding AG's price-to-earnings ratio is -- while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$29.4M ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns OCS or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Oculis Holding AG's net margin of 4.44%. Oculis Holding AG's return on equity of -68.98% beat BeOne Medicines Ltd.'s return on equity of 7.54%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.53 $250.4M ONCBeOne Medicines Ltd.88.43% $0.58 $6.4B -
What do Analysts Say About OCS or ONC?
Oculis Holding AG has a consensus price target of $48.15, signalling upside risk potential of 69.28%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $409.68 which suggests that it could grow by 37.03%. Given that Oculis Holding AG has higher upside potential than BeOne Medicines Ltd., analysts believe Oculis Holding AG is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 ONCBeOne Medicines Ltd.17 0 1 -
Is OCS or ONC More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.532, suggesting its less volatile than the S&P 500 by 46.826%.
-
Which is a Better Dividend Stock OCS or ONC?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or ONC?
Oculis Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.5B. Oculis Holding AG's net income of -$29.4M is lower than BeOne Medicines Ltd.'s net income of $66.8M. Notably, Oculis Holding AG's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 118.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 6.33x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$29.4M ONCBeOne Medicines Ltd.6.33x 118.52x $1.5B $66.8M
-
Which has Higher Returns OCS or SPHDF?
Santhera Pharmaceuticals Holding AG has a net margin of -- compared to Oculis Holding AG's net margin of --. Oculis Holding AG's return on equity of -68.98% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.
Company Gross Margin Earnings Per Share Invested Capital OCSOculis Holding AG-- -$0.53 $250.4M SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M -
What do Analysts Say About OCS or SPHDF?
Oculis Holding AG has a consensus price target of $48.15, signalling upside risk potential of 69.28%. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Oculis Holding AG has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe Oculis Holding AG is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings OCSOculis Holding AG7 0 0 SPHDFSanthera Pharmaceuticals Holding AG0 0 0 -
Is OCS or SPHDF More Risky?
Oculis Holding AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.872, suggesting its less volatile than the S&P 500 by 187.184%.
-
Which is a Better Dividend Stock OCS or SPHDF?
Oculis Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oculis Holding AG pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OCS or SPHDF?
Oculis Holding AG quarterly revenues are --, which are larger than Santhera Pharmaceuticals Holding AG quarterly revenues of --. Oculis Holding AG's net income of -$29.4M is higher than Santhera Pharmaceuticals Holding AG's net income of --. Notably, Oculis Holding AG's price-to-earnings ratio is -- while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oculis Holding AG is -- versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OCSOculis Holding AG-- -- -- -$29.4M SPHDFSanthera Pharmaceuticals Holding AG4.78x 1.45x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 2% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is up 0.81% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 4.39% over the past day.
